Outlook is neutral, with stock confined to a range of ±8%
Strategy has +106% ROI potential and 19% overvalued
Outlook is neutral, with stock confined to a band of ±8%
Strategy has +119% ROI potential and 12% overvalued
MRNA Moderna190.58-12.63 (-6.2%)
Outlook is neutral, with stock confined to a span of ±13%
Strategy has +86% ROI potential and 8% overvalued
Outlook is neutral, with stock confined to a band of ±12%
Strategy has +85% ROI potential and 14% overvalued